Abstract:

Abstract：Patients with chronic kidney disease (CKD) have higher risk of cardiovascular disease (CVD).CVD is also an important predictor of CKD progressing. Mineral and bone disorder (MBD) in CKD patients including increased serum intact parathyroid hormone (iPTH), vitamin D deficiency and hyperphosphatemia are attributed as independent risk factors of CVD. FGF23 regulates phosphorus and vitamin D metabolism. Its levels increase progressively in early CKD，partially as adaptive changes to the uremic status but also as primary pathophysiological events that may account for adverse clinical manifestations including bone and cardiovascular complications. Increased FGF23 is associated with left ventricular hypertrophy (LVH), vascular calcification, cardiovascular dysfunction, and increased mortality in CKD patients. In this brief manuscript, physiology of FGF23, association between plasma FGF23 level and CVD, the mechanism linked FGF23 to CVD, and the clinical intervention options will be discussed.

Key words: chronic kidney disease, cardiovascular disease, fibroblast growth factor 23